- University of Virginia School of Law (J.D., 2013) editorial board member, Virginia Law Review
- University of California, Berkeley (B.A., Molecular and Cell Biology, 2009) with Honors
Elizabeth Tuan is a litigation associate in the Los Angeles office of Irell & Manella LLP. Ms. Tuan’s practice focuses primarily on patent litigation in a wide range of industries, including biotechnology and medical devices. Recently, she represented a cancer immunotherapy company, the exclusive licensee of a patent claiming a novel cancer treatment, in pursuing infringement of the patent. The litigation ended in a favorable settlement.
Ms. Tuan’s practice includes representing clients in post-grant proceedings challenging the validity of issued patents before the U.S. Patent and Trademark Office. Most recently, Ms. Tuan represented a patent owner in an inter partes review and successfully secured a final written decision rejecting each of the Petitioner’s validity challenges in that proceeding.
Ms. Tuan also maintains an active pro bono practice. Most recently, she successfully argued on behalf of pro bono clients in front of the California Court of Appeal, which affirmed the decision of the trial court denying a petition to compel arbitration. The case settled successfully. Ms. Tuan is also a member of the firm’s Hiring, Diversity, and Summer Committees.
Ms. Tuan earned her J.D. from the University of Virginia School of Law, where she was a member of the Virginia Law Review editorial board and participated in the annual William Minor Lile Moot Court Competition. While in law school, Ms. Tuan served as a legal extern to the Honorable Deborah J. Saltzman of the United States Bankruptcy Court for the Central District of California. She earned her B.A. in Molecular and Cell Biology, with Honors, from the University of California, Berkeley.
Ms. Tuan is conversant in Mandarin Chinese.
- Juno Therapeutics, Inc. et al. v. Kite Pharma, Inc. (D. Del.)
Currently representing Juno Therapeutics, Memorial Sloan Kettering Cancer Center, and Sloan Kettering Institute for Cancer Research in declaratory judgment action of patent infringement relating to chimeric antigen receptor technology for the treatment of B cell cancers.
- Kite Pharma, Inc. v. Sloan Kettering Institute for Cancer Research (PTAB)
Currently representing patent owner Sloan Kettering Institute for Cancer Research and exclusive licensee Juno Therapeutics, Inc. in an inter partes review proceeding relating to chimeric antigen receptor technology. The U.S. Patent and Trademark Office issued a final written decision upholding all claims of the patent.
- Koninklijke Philips N.V. et. al. v. ZOLL Lifecor Corp (W.D. Pa.)
Currently representing ZOLL Lifecor Corp. in patent litigation relating to external defibrillator technology.
- RainDance Technologies et al. v. 10X Genomics (D. Del.)
Currently representing 10X Genomics in a patent litigation suit relating to methods of preparing DNA samples for sequencing through the use of microfluidic technology.
- Juno Therapeutics Inc. et al. v. Novartis Pharmaceuticals Corp. et al. (E. D. Pa.)
Represented Juno Therapeutics in patent and contract dispute surrounding chimeric antigen receptor T-cell therapies for the treatment of B cell cancers. The case settled favorably after several years of litigation, with Juno receiving upfront and milestone payments from Novartis, as well as ongoing royalties.
- 2013, California
- U.S. District Court, Central District of California